Advertisement

Ethical Consideration

  • Michael Fuchs
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 737)

Abstract

The twofold distinction between interventions into the germ line and interventions into somatic cells on the one hand and between the treatment of diseases and enhancement on the other hand resulted in the concept of somatic gene therapy. There is a nearly unanimous agreement that somatic gene therapy has a high-ranking moral objective and uses methods that extend current techniques for treating diseases in a morally acceptable way. In its experimental phase principles of research ethics as the autonomy and the informed consent of the patient or the test person, a fair selection of test persons and a careful weighing of risks and benefits have to be taken into account and several specific points have to be considered. Experimental somatic gene therapy requires a positive vote of a competent and independent ethics committee.

Key words

Somatic gene therapy Enhancement Informed consent Effects on the germ line Gene doping Risk management 

References

  1. 1.
    Anderson, W. F. (1985) Human gene therapy: Scientific and ethical considerations J Med Phil 10, 275–91.Google Scholar
  2. 2.
    Wolstenholme, G. E. W. (ed.) (1963) Man and his future: A CIBA foundation volume (Boston: Little, Brown).Google Scholar
  3. 3.
    Walters, L. (1991) Ethical issues in human gene therapy J Clin Eth 2, 267–74.Google Scholar
  4. 4.
    Walters, L., Palmer, J. G. (1997) The ethics of human gene therapy (New York, Oxford: Oxford University Press).Google Scholar
  5. 5.
    Rabino, I. (2003) Ethical issues Theor Med Bioeth 24, 31–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Der Bundesminister für Forschung und Technologie (ed.) (1985) In-vitro-Fertilisation, Genomanalyse und Gentherapie. Bericht der gemeinsamen Arbeitsgruppe des Bundesministers für Forschung und Technologie und des Bundesministers der Justiz (München: Schweitzer).Google Scholar
  7. 7.
    Comité Consultatif National d’Éthique pour les Sciences de la Vie et de la Santé (CCNE) (1990) Opinion on gene therapy. N° 22 – December 13, 1990.Google Scholar
  8. 8.
    Montgolfier, S. (2000) La thérapie génique humain, http://www.ethique.inserm.fr/inserm/ethique.nsf/937238520af658aec125704b002bded2/fd217f8102758fefc12570a500515225? OpenDocument (2009-11-05).
  9. 9.
    European Society of Gene Therapy (ESTG) (2002) Position paper on social, ethical and public awareness issues in gene therapy.Google Scholar
  10. 10.
    De Wachter, M. A. M. (1993) Experimental (somatic) gene therapy. Ethical concerns and control (Maastricht: Instituut voor Gezon­dhei­dsethiek).Google Scholar
  11. 11.
    National Commission for the Protection of Biomedical and Behavioral Research (1978) Report and recommendations institutional review boards (Washington, DC: US Government Printing Office).Google Scholar
  12. 12.
    Fuchs, M., Heyer, M., Fischer, N. (2006) Provision of support for producing a European directory of local ethics committees (LECs): Draft final report.Google Scholar
  13. 13.
    Frankel, M., Chapman, A. (2000) Human inheritable genetic modifications. Assessing scientific, ethical, religious and policy issues (Washington, DC: American Association for the Advancement of Science).Google Scholar
  14. 14.
    Rehmann-Sutter, C. (2003) Keimbahnverän­derungen in Nebenfolge? Ethische Überle­gungen zur Abgrenzbarkeit der somatischen Gentherapie, in: Rehmann-Sutter, C., Müller, H. (ed.) Ethik und Gentherapie. Zum praktischen Diskurs um die molekulare Medizin (2nd ed. Tübingen: Francke), 187–205.Google Scholar
  15. 15.
    Council of Europe (COE) Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine.Google Scholar
  16. 16.
    Anderson, W. F. (1989) Human gene therapy: Why draw a line? J Med Phil 14, 681–93.Google Scholar
  17. 17.
    Glover, J. (1984) What sort of people should there be? (Harmondsworth: Penguin).Google Scholar
  18. 18.
    Redlich, F. C. (1976) Editorial reflections on the concepts of health and disease J Med Phil 1, 269–80.Google Scholar
  19. 19.
    Silvers, A. (1994) “Defective” agents. Equality, difference and tyranny of the normal J Soc Phil 25, 154–75.CrossRefGoogle Scholar
  20. 20.
    Sinsheimer, R. L. (1987) The prospect of designed genetic change, in: Chadwick, R. F. (ed.) Ethics, reproduction and genetic control (London, New York, Sydney: Routledge), 136–46.Google Scholar
  21. 21.
    Torres, J. M. (1997) On the limits of enhancement in human gene transfer: Drawing the line J Med Phil 22, 43–53.Google Scholar
  22. 22.
    Krimsky, S. (1990) Human gene therapy: Must we know to stop before we start? Hum Gene Ther 1, 171–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Juengst, E. T. (1997) Can enhancement be distinguished from prevention in genetic medicine? J Med Phil 22, 125–42.Google Scholar
  24. 24.
    Fuchs, M., Lanzerath, D., Sturma, D. (2008) Natürlichkeit und Enhancement: Zur ethischen Beurteilung des Gendopings; Gutachten des Instituts für Wissenschaft und Ethik e.V. (IWE) im Auftrag des Deutschen Bundestages Jahrbuch für Wissenschaft und Ethik 13, 263–302.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011 2011

Authors and Affiliations

  1. 1.Institut für Wissenschaft und EthikUniversity BonnBonnGermany

Personalised recommendations